Analysis of clinical trials reveals urgent need to increase Alzheimer’s drug development Analysis of clinical trials shows pipeline for therapeutics is little; 99.6 % of drug attempts fail Researchers at the Cleveland Clinic Lou Ruvo Middle for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease , revealing an urgent have to raise the number of agents entering the AD medication advancement pipeline and progressing successfully towards new therapy treatments. The paper, ‘Alzheimer's Disease Drug Development Pipeline: Few Candidates, Frequent Failures,’ was published today in the journal Alzheimer's Analysis & Therapy .

médecine douce

Anacor finds novel mechanism for lead anti-fungal drug, AN2690 Anacor Pharmaceuticals, a privately held pharmaceutical company, has announced that the journal Research shall publish results of research that information how AN2690, the company’s lead clinical candidate, kills fungal cells by interfering with synthesis of a particular protein required for fungal growth. This original mechanism of action, permitted by the company’s boron-based chemistry, could also verify useful in developing fresh classes of therapeutic brokers such as antibiotics.